Equilab International is a leading Contract Research Organization (CRO) in Southeast Asia who provides bioavailability/bioequivalence study, clinical trial and analytical services. As the first CRO in Southeast Asia that is certified by WHO and UK-MHRA, we are in compliance with international GCP and GLP standards. Our study reports have been approved in UK, Netherland, Poland, Spain, Hungary, Afghanistan, Sri Lanka, Bangladesh, Hong Kong, Taiwan, and all Southeast Asia countries. Currently, we are also involved in global trials for Covid-19 vaccine studies. Our existing customers come from Asia, Australia, Africa, America, Europe, and MNC's global.